Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Between Oct 12 and Oct 20, 2026, enterprise software and infrastructure vendors moved together to operationalize agentic AI. Salesforce agreed to buy Braze to add real-time customer-engagement data. ServiceNow launched AI Passport and expanded its agent-governance control tower. Intuit pushed AI into accounting and into international markets. Cisco, NVIDIA, Marvell and Hesai build out the networking, silicon, local-compute and physical-AI data layers beneath them. A counter-current of AI-safety concern, shown by OpenAI's safety-transparency lead quitting and OpenAI's response of adding monitors to training runs, shows trust and governance becoming a gating factor.
Across mid- and small-cap issuers, October 2026 brought a cluster of governance events: interim CEO handoffs (Fox Factory, Keyser's move to advisor), board refreshes, shareholder-vote-driven restructurings (Odyssey's merger vote and 1-for-25 reverse split, the NGEx spin-out) and a contested situation at Boardwalktech, where ZenaTech asked regulators to intervene. Several of these are tied to weak results or reduced guidance (Fox Factory's Q3 miss and Marucci divestiture), and boards are leaning on unanimous-recommendation and 'accomplished executive' messaging to project stability. Steadier names such as Vivendi (lower net debt, Gameloft-led revenue growth) and Value Line (regular $0.35 dividend) are a contrast, so overall sentiment is mixed.
In the second week of October 2026, Palantir announced a cluster of AI partnerships with Customers Bank, Ondas (Regna AI), Armada and Surf Air Mobility (OperatorOS). Four Seeking Alpha analysts turned or stayed bullish, citing customer expansion, net dollar retention and a Goldman Sachs upgrade. In contrast, J.P. Morgan's Seth Seifman describes weak, sour sentiment in aerospace and defense (a Leidos downgrade, Boeing cash-flow doubts) even with the broader market near highs. Fiscal 2027 budget uncertainty after the Nov. 3 midterms hangs over that group, while quantum names such as D-Wave look stretched on valuation.
October 2026 brings a cluster of oncology catalysts. Positive CHMP opinions (RASONQUE in pancreatic cancer, an updated Libtayo regimen), an FDA approval (Tecentriq in adjuvant dMMR colon cancer) and heavy ESMO data from AbbVie, intismeran and others support a constructive sector tone. Meanwhile AstraZeneca's AI-enabled 'lab of the future' and agentic biologics design, plus ADC-focused small caps like Akari and consolidation such as McKesson/CD&R's Option Care Health deal, point to capital and talent moving toward AI-accelerated, ADC-centred oncology pipelines.
Small and mid-cap biotechs (MindWalk, Everest, Idorsia, Akari, Ernexa, Prelude, MapLight) are hiring translational, discovery and business-development leaders ahead of IND filings and Phase 1/2 readouts. Royalty and milestone income (BioArctic's Leqembi royalties, VivoSim's Eli Lilly milestones, Lilly's obesity and diabetes demand) is funding them. Idorsia's CEO handover and Kimi models being jailbroken to give bioweapon instructions show governance and AI-biosecurity risk building alongside the growth. The AI-finance link is thin: the facts contain no direct fintech or trading content, so the AI angle is mostly biosecurity and the finance angle is royalty and milestone revenue.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedPranešimas apie AB „Vilkyškių pieninė“ eilinio visuotinio akcininkų susirinkimo sušaukimą
“Pranešimas apie AB „Vilkyškių pieninė“ eilinio visuotinio akcininkų susirinkimo sušaukimą AB „Vilkyškių pieninė“ (toliau – Bendrovė), įmonės kodas 277160980, valdybos iniciatyva ir sprendimu 2026 m…”
New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players
“New platform Suomi-kasinot.fi launches to simplify online casino choices for Finnish players Helsinki, April 05, 2026 (GLOBE NEWSWIRE) -- As Finland’s gambling market moves toward a major regulatory shift, a new comparison platform, Suomi-kasinot.fi, has been launched to help Finnish players navigate the growing number…”
Chris Raub Named President and CEO of PPM America, Inc.
“Chris Raub Named President and CEO of PPM America, Inc. LANSING, Mich. & CHICAGO, April 09, 2026--(BUSINESS WIRE)--Jackson Financial Inc.i (NYSE: JXN) (Jackson®) and PPM America, Inc…”
Indice des dettes à la consommation de MNP : les Canadiens subissent les contrecoups financiers de l’incertitude économique persistante
“Indice des dettes à la consommation de MNP : les Canadiens subissent les contrecoups financiers de l’incertitude économique persistante CALGARY, Alberta, 13 avr…”
Michigan woman reluctant to bail on coveted 2.8% mortgage rate. The Ramsey Show tells her it’s not even a real question
“Michigan woman reluctant to bail on coveted 2.8% mortgage rate. The Ramsey Show tells her it’s not even a real question Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…”
Tribal Loans Are On The Rise — And TribalLoans.com Might Be the Reason Why
“Tribal Loans Are On The Rise — And TribalLoans.com Might Be the Reason Why New York, NY, March 27, 2026 (GLOBE NEWSWIRE) -- Let's be honest…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
Via News tracked a US-led fintech wave, from retail event contracts to AI-agent identity startups. Little of it is European, and the dossier names no EU regulator. We lead with Robinhood's SEC-checked figures and flag where sources diverge or are weak.
Analysts are upgrading Palantir while J.P. Morgan warns on defence stocks. The dossier holds little European-specific evidence, so we say so. We separate verified figures, analyst opinion and our own reading, and flag where the sources are weak.
EU regulators are backing newer cancer treatments, and AI is billed as the long-term engine. But the one company with checked SEC figures, Summit Therapeutics, lost $1.08 billion in FY2025 with no revenue. Several AI claims are forecasts from a source that failed our reliability check.
AI spending is spreading from chips to networking, physical-world data and customer-service software. Nvidia's audited cost of sales shows how fast. The dossier says little about EU rules, and safety scrutiny of OpenAI is rising. Verified filings are separated from company claims.
SAP, Zeta and others are launching agent platforms, while the smaller deals show money flowing to the layers that keep agents in check. Our dossier has little on EU regulation, so we say so. It does contain a clear argument that rules must be enforced by the system, and a warning not to trust AI with finance arithmetic.
A CHMP opinion for Trodelvy, a German-first Optune Pax launch and real-world German data on mogamulizumab give Europe its own oncology story in a US-heavy October. Summit's SEC-verified accounts show how costly the biggest catalyst, ivonescimab, is to reach. Some sources here fared poorly in our reliability checks.
A French networking tie-up and a Dutch equipment maker sit at the European edge of an AI-driven memory and interconnect squeeze. SEC-verified Micron filings show how fast its spending has grown. We separate the checked figures from analyst opinion and flag where the sources are weak.
Three oncology storylines are converging: new-modality drugs nearing decisions, AI-built biologics, and a care-delivery buyout. For European readers the clearest signals are an EMA committee opinion and a Swiss-based device maker's EU launch. Summit's checked SEC filings show what a late-stage bet costs. Source reliability is flagged throughout.
Verified SEC data show Micron's annual capital spending nearly doubled to $15.9bn in fiscal 2025. Meanwhile Nvidia is locking down memory supply, and France's Kalray and Bull are pursuing AI networking. Much of the supporting reporting is only partly reliable, and we show where.
The EU regulator has backed a new first-line breast cancer combination and Novocure has won a CE Mark, while US decisions on ivonescimab and a personalised mRNA vaccine arrive by 14 November. Merck's SEC-verified numbers show cash moving sharply and capex falling. Our sources vary widely in reliability, and we say where.
A European regulator backed a new first-line breast cancer combination, and a Swiss-based device maker reported record revenue while opening a German launch. Behind both sits a pipeline built on AI, mRNA and antibody-drug combinations. We separate what is verified from what is still a claim.
SEC-filed figures show Micron's capital spending almost doubled in a year and its cash pile reached $25 billion. Analysts are bullish on AI-infrastructure names but flag stretched valuations. The dossier holds little EU regulatory material, and we say so.
SEC-filed figures show Micron's capital spending nearly doubled in a year, while Europe's visible role is ASML's rally and a Kalray–Bull networking pact. Analysts' 33% to 49% upside calls come from a source whose claims held up only 22% of the time in our checks.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only about 45% of company data and only about half trust their agents. Deals from Manulife, Box and Nvidia show where the money is going. That source scores poorly on our reliability check, so we flag it.
Mattel, Verra Mobility, BellRing and Brown-Forman have all named or are seeking new chief executives, while boards from Dublin to Amsterdam run shareholder-vote processes. The dossier is thin on Heineken and EU regulation, so we report what it supports. The picture is calm on the surface, and Brown-Forman and Kneat are the exceptions.
Agentic AI is pulling Big Tech, venture money and incumbents into enterprise software. Via News traced this to checked filings and interviews, not forecasts. The European evidence is thin but concrete: Paris-listed 74Software's buyback and Europe-based Light. Governance, not model quality, looks like the limit.
A survey says every organisation will use agentic AI within two years, with company data as the bottleneck. That survey source scores 0% on our reliability check, so we treat it as a claim to test. Verified Nvidia filings and named company deals give firmer ground. Europe's role in this material is thin, and we say so.
Europe's regulator has backed a new first-line breast cancer combination, and a Swiss-based device maker posted record revenue. The AI-biologics story behind the optimism rests on a source where none of 11 checked claims held up. Here is what the checked data supports.
A survey reported by MIT Technology Review says 100% of respondents plan to use agentic AI within two years, yet the supporting data is weaker than the headline. The source has a poor measured reliability record. Nvidia's audited accounts and the Manulife, Box and Nomura announcements are firmer ground.
SEC filings show Micron's quarterly capital spending rose from $1.8bn to $5.4bn in two years and its cash pile reached $25bn. Analyst enthusiasm is heavily concentrated in AI infrastructure, and the sources behind much of it have mixed track records. Little of the dossier is explicitly European, and we say where.
Every respondent in a new MIT Technology Review study plans to use agentic AI within two years, yet companies give AI access to only 45% of their data. The European angle is thin in our verified material. What we can check is Nvidia's audited numbers and where the claims come from.
Vertical AI agents are pitched at banks, insurers and regulated back offices, where auditability decides the sale. Our checked data shows spending on AI hardware rising sharply. The main source for the 'trust gap' comes from a publisher whose checked claims have a poor record.
Mistral AI, France's leading AI lab, is a customer of Nvidia's US-built infrastructure — about the extent of hard European detail in this global agentic-AI story. A Google Cloud-linked adoption survey, plus Manulife, Box and C3.ai filings, sketch the trust picture, but Via News found the survey source failed nearly every reliability check it ran.
Google has loosened its AI watermark rules and OpenAI has lost another senior executive, but the more concrete story for European business is elsewhere: Spain's Multiverse Computing and Germany's Black Forest Labs are posting benchmarked efficiency gains while some of the loudest US capex and opportunity claims trace to low-reliability sources.
A Grenoble-based chipmaker's new AI-networking tie-up with Bull lands the same week SOXX has fallen 25% from its highs — evidence that the divergence between deal-making and equity sentiment now runs through Europe too, verified against original filings and press releases.
A late-July rout wiped tens of billions off AI-chip stocks even as SK Hynix, Nvidia and Washington doubled down on the buildout. Via News traces the numbers — from a Grenoble networking deal to Vicor's audited revenue — to separate the correction from the cycle.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.
